Form 4: Tom Y. Lee Acquires Stock Options in PURE Bioscience, Inc.
SEC Form 4 Filing
Director Tom Y. Lee acquired stock options in PURE Bioscience, Inc. on August 20, 2024.
Summary
- On August 20, 2024, Tom Y. Lee, a director of PURE Bioscience, Inc., acquired stock options to purchase 125,000 shares of common stock.
- The exercise price of these options is $0.07 per share.
- The options vest in two tranches: 50% on the earlier of January 15, 2025, or the date of the 2025 annual meeting, and the remaining 50% on the earlier of January 15, 2026, or the date of the 2026 annual meeting.
- The options expire on August 20, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The acquisition of options by a director could be interpreted slightly positively, but it's primarily an informational disclosure.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of transaction: Tom Y. Lee acquired stock options. |
| 01/15/2025 | First possible vesting date for 50% of the options. |
| 01/15/2026 | Second possible vesting date for 50% of the options. |
| 08/20/2034 | Expiration date of the stock options. |
Keywords
stock options, PURE Bioscience, Form 4, director, beneficial ownership, Tom Y. Lee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.